Clearstead Advisors’s iRadimed IRMD Stock Holding History

Clearstead Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.72K	Hold	49	–	–	﹤0.01%	1748
2025 Q4	$4.77K	Hold	49	–	–	﹤0.01%	2028
2025 Q3	$3.49K	Buy	+49	New	+$3.27K	﹤0.01%	2289
2025 Q1	–	Sell	-178	Closed	-$9.79K	–	2258
2024 Q4	$9.79K	Buy	178 +10	+6%	+$526	﹤0.01%	1568
2024 Q3	$8.45K	Buy	168 +49	+41%	+$2.26K	﹤0.01%	1616
2024 Q2	$5.23K	Buy	119 +7	+6%	+$298	﹤0.01%	1683
2024 Q1	$4.75K	Buy	112 +58	+107%	+$2.56K	﹤0.01%	1183
2023 Q4	$2.56K	Buy	+54	New	+$2.27K	﹤0.01%	1253

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearstead Advisors's IRMD Position: Q1 2026 in Review

Clearstead Advisors held its iRadimed (IRMD) position steady in Q1 2026 at 49 shares worth $4.72K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Clearstead Advisors first reported a position in IRMD in Q4 2023 and has held it in 8 quarters since. The position peaked at $9.79K in Q4 2024. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Clearstead Advisors held 49 shares of iRadimed worth $4.72K as of Q1 2026.
Clearstead Advisors left its iRadimed share count unchanged in Q1 2026.
iRadimed made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #1748 holding.
Clearstead Advisors first reported a position in iRadimed in Q4 2023 and has held it in 8 quarters since.
Clearstead Advisors's iRadimed position peaked at $9.79K in Q4 2024.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.